Contributing to efficient API process development using asymmetric synthesis technology

In recent years, there have been cases where new compounds with extremely complicated chemical structures and compounds with unknown physical properties have been identified as new drug candidates, and SPERA P...

Control of Potential Mutagenic Impurities: PMIs

Recently, health authorities pay attention to residual impurities in drug substances and drug products, and require pharmaceutical companies to control them strictly. Especially, the inquiries on PMIs control...

Chiral technology at SPERA PHARMA

One of the characteristic technologies that SPERA PHARMA took over from Takeda Pharmaceutical Company is chiral technology developed over many years in the Process Chemistry Division. All equipment and researc...


now loading.

page top